BioVeda China Fund backs Jaguar Animal Health


Jaguar Animal Health has held an initial $2m closing of its Series A round of financing led by private equity and growth capital investor BioVeda China Fund (BVCF).

BioVeda said it will invest another $3m by the end of February 2014.

Jaguar was founded with seed funding and resources from Napo Pharmaceuticals, and existing Napo investors.

Jaguar focuses on the development and commercialisation of healthcare for the global veterinary marketplace from plants used traditionally in rainforest areas.

Jaguar’s products will target companion animals, racing animals and food and farm animals with prescription pharmaceuticals and nutraceuticals.

The proceeds of the Series A financing will be used for operations including studies of a new pharmaceutical compound other botanical extract/nutraceutical products. Funds will also be used to complete market studies, hiring of personnel, establishing manufacturing capabilities, and regulatory activities, the company said.

Dr Zhi Yang, and founder and managing director of BVCF said, “We are very pleased to be making our first investment in animal health for the world markets. This is a focus for us and we plan to expand our portfolio of investments in companies involved in animal health and food security.”

BVCF specialises in China’s life sciences and healthcare industry, with investors including institutional limited partners and MNC pharmaceutical companies.

Copyright © 2014 AltAssets